دورية أكاديمية
Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study.
العنوان: | Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study. |
---|---|
المؤلفون: | Aebi-Popp K; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern 3010, Switzerland.; Department of Obstetrics and Gynecology, Lindenhofspital, Bern 3012, Switzerland., Kahlert CR; Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St Gallen 9000, Switzerland., Crisinel PA; Unit of Pediatric Infectious Diseases and Vaccinology, Service of Pediatrics, Women and Mother Child Department, Lausanne University Hospital and University of Lausanne, Lausanne 1011, Switzerland., Decosterd L; Department of Laboratory Medicine and Pathology, Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne 1011, Switzerland., Saldanha SA; Department of Laboratory Medicine and Pathology, Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne 1011, Switzerland., Hoesli I; Department of Obstetrics and Gynecology, University Hospital Basel and University of Basel, Basel 4031, Switzerland., Martinez De Tejada B; Department of Pediatrics, Gynecology and Obstetrics, Obstetrics Division, University Hospitals of Geneva and Faculty of Medicine, University of Geneva, Geneva 1211, Switzerland., Duppenthaler A; Division of Infectious Diseases, University Children's Hospital, Bern 3010, Switzerland., Rauch A; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern 3010, Switzerland., Marzolini C; Division of Infectious Diseases and Hospital Epidemiology, University Hospital and University of Basel, Basel 4031, Switzerland.; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L693GF, UK. |
مؤلفون مشاركون: | Swiss Mother and Child HIV Cohort Study (SHCS) |
المصدر: | The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2022 Nov 28; Vol. 77 (12), pp. 3436-3442. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Internet ISSN: 1460-2091 (Electronic) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 1997- : London : Oxford University Press Original Publication: London, New York, Academic Press. |
مواضيع طبية MeSH: | Anti-HIV Agents*/therapeutic use , HIV Infections*, Female ; Humans ; Infant ; Anti-Retroviral Agents/therapeutic use ; Cohort Studies ; Darunavir/therapeutic use ; Milk, Human ; Mothers ; Prospective Studies ; Raltegravir Potassium/therapeutic use ; Rilpivirine/therapeutic use ; Ritonavir/therapeutic use ; Switzerland |
مستخلص: | Introduction: In 2018, Switzerland changed its guidelines to support women living with HIV wishing to breastfeed. The exposure of antiretroviral drugs (ARVs) in breastmilk and the ingested daily dose by the breastfed infant are understudied, notably for newer ARVs. This study aimed to quantify ARV concentrations in maternal plasma and breastmilk to determine the milk/plasma ratio, to estimate daily infant ARV dose from breastfeeding and to measure ARV concentrations in infants. Methods: All women wishing to breastfeed were included, regardless of their ARV treatment. Breastmilk and maternal plasma samples were mostly collected at mid-dosing interval. Results: Twenty-one mother/child pairs were enrolled; of those several were on newer ARVs including 10 raltegravir, 1 bictegravir, 2 rilpivirine, 2 darunavir/ritonavir and 3 tenofovir alafenamide. No vertical HIV transmission was detected (one infant still breastfed). The median milk/plasma ratios were 0.96/0.39 for raltegravir once/twice daily, 0.01 for bictegravir, 1.08 for rilpivirine, 0.12 for darunavir/ritonavir and 4.09 for tenofovir alafenamide. The median estimated infant daily dose (mg/kg) from breastfeeding was 0.02/0.25 for raltegravir once/twice daily, 0.01 for bictegravir, 0.02 for rilpivirine, 0.05 for darunavir/ritonavir and 0.007 for tenofovir alafenamide, resulting in relative infant dose <10% exposure index for all ARVs. Conclusions: ARVs were transferred to a variable extent in breastmilk. Nevertheless, the estimated daily ARV dose from breastfeeding remained low. Differential ARV exposure was observed in breastfed infants with some ARVs being below/above their effective concentrations raising the concern of resistance development if HIV infection occurs. More data on this potential risk are warranted to better support breastfeeding. (© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.) |
References: | PLoS Med. 2011 Mar;8(3):e1000430. (PMID: 21468304) Pediatr Infect Dis J. 2013 Apr;32(4):e164-9. (PMID: 23249916) Nat Med. 2005 Feb;11(2):127-9. (PMID: 15685169) Clin Infect Dis. 2021 Sep 7;73(5):e1200-e1207. (PMID: 33346335) Antimicrob Agents Chemother. 2009 Jul;53(7):2852-6. (PMID: 19433563) Antimicrob Agents Chemother. 2011 Jul;55(7):3527-33. (PMID: 21518840) Front Pharmacol. 2021 Aug 13;12:734760. (PMID: 34483946) J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465-472. (PMID: 29649076) J Acquir Immune Defic Syndr. 2021 Oct 1;88(2):206-213. (PMID: 34108383) Curr Pharm Des. 2019;25(5):556-576. (PMID: 30894103) Clin Pharmacol Drug Dev. 2021 Sep;10(9):985-993. (PMID: 34265164) PLoS Med. 2016 Sep 27;13(9):e1002132. (PMID: 27676257) Mol Pharm. 2013 Jun 3;10(6):2340-9. (PMID: 23617680) HIV Med. 2007 Jan;8(1):1-7. (PMID: 17305925) AIDS. 2020 Oct 1;34(12):1863-1865. (PMID: 32675580) J Antimicrob Chemother. 2015 Apr;70(4):1139-45. (PMID: 25525195) J Mass Spectrom. 2013 May;48(5):616-25. (PMID: 23674286) N Engl J Med. 2000 Jul 13;343(2):118-26. (PMID: 10891521) PLoS Med. 2019 Sep 20;16(9):e1002895. (PMID: 31539371) Clin Pharmacol Drug Dev. 2019 May;8(4):480-491. (PMID: 30412360) J Antimicrob Chemother. 2015 Jul;70(7):1928-41. (PMID: 25858354) J Mass Spectrom. 2020 Jun;55(6):e4506. (PMID: 32160389) J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Apr 15;877(11-12):1057-69. (PMID: 19332396) Pharmacol Res Perspect. 2017 Oct;5(5):. (PMID: 28971607) Antivir Ther. 2012;17(8):1503-6. (PMID: 22910400) Antimicrob Agents Chemother. 2005 Feb;49(2):680-4. (PMID: 15673751) Swiss Med Wkly. 2018 Jul 23;148:w14648. (PMID: 30044473) Antimicrob Agents Chemother. 2013 Nov;57(11):5472-7. (PMID: 23979733) Lancet HIV. 2018 Sep;5(9):e531-e536. (PMID: 29960731) J Pharm Pharmacol. 2016 Nov;68(11):1359-1365. (PMID: 27671833) Clin Infect Dis. 2015 Aug 1;61(3):453-63. (PMID: 25882300) |
فهرسة مساهمة: | Investigator: AI Abela; K Aebi-Popp; A Anagnostopoulos; M Battegay; E Bernasconi; DL Braun; HC Bucher; A Calmy; M Cavassini; A Ciuffi; G Dollenmaier; M Egger; L Elzi; J Fehr; J Fellay; H Furrer; CA Fux; HF Günthard; A Hachfeld; D Haerry; B Hasse; HH Hirsch; M Hoffmann; I Hösli; M Huber; CR Kahlert; L Kaiser; O Keiser; T Klimkait; RD Kouyos; H Kovari; K Kusejko; G Martinetti; B Martinez de Tejada; C Marzolini; KJ Metzner; N Müller; J Nemeth; D Nicca; P Paioni; G Pantaleo; M Perreau; A Rauch; P Schmid; R Speck; M Stöckle; P Tarr; A Trkola; G Wandeler; S Yerly |
المشرفين على المادة: | 0 (Anti-HIV Agents) 0 (Anti-Retroviral Agents) 8GB79LOJ07 (bictegravir) YO603Y8113 (Darunavir) 43Y000U234 (Raltegravir Potassium) FI96A8X663 (Rilpivirine) O3J8G9O825 (Ritonavir) |
تواريخ الأحداث: | Date Created: 20220930 Date Completed: 20221202 Latest Revision: 20221212 |
رمز التحديث: | 20221212 |
مُعرف محوري في PubMed: | PMC9704434 |
DOI: | 10.1093/jac/dkac337 |
PMID: | 36177836 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1460-2091 |
---|---|
DOI: | 10.1093/jac/dkac337 |